All In Biotech

Drug Trial Radar · NCT03401385

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Phase 1, Two-part, Multicenter, Open-label, Multiple Dose, First-in-human Study of DS-1062a in Subjects With Advanced Solid Tumors (TROPION-PanTumor01)

Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 890 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

890

Planned (sponsor's estimate)

Start

Jan 31, 2018

Primary completion

Jan 1, 2028

Study completion Jan 1, 2028

Sponsor

Lead sponsor
Daiichi Sankyo Co., Ltd.Daiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
Daiichi Sankyo; AstraZeneca
First posted
Jan 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is one single group of participants with non-small cell lung cancer (NSCLC) who have not been cured by other treatments. It is the first time the drug has been used in humans. There will be two parts and a sub-study. The primary purpose of the parts are: * Dose Escalation: To investigate the safety and tolerability and to determine the maximum tolerated dose (MTD) and the recommended dose for expansion (RDE) of DS-1062a * Dose Expansion: To investigate the safety and tolerability of DS-1062a in additional solid tumors This study is expected to last approximately 6 years from the time the first participant is enrolled to the time the last subject is off the study. Study sites are located in both the United States and Japan. The number of treatment cycles is not fixed in this study. Participants who continue to benefit from the study treatment may continue, unless: * they withdraw * their disease gets worse * they experience unacceptable side effects. The primary purpose of the sub-study is to compare the effectiveness of steroid versus non-steroid mouthwash as prophylaxis against oral mucositis/stomatitis in participants receiving DS-1062a. The sub-study is a randomized study that will include approximately 76 participants enrolling into the Dose Expansion part.

Conditions

  • Hormone Receptor Positive Breast Cancer
  • Triple Negative Breast Cancer
  • Non-small Cell Lung Cancer

Interventions

  • Datopotamab Deruxtecan (Dato-DXd)Drug

    A total anti-TROP2 antibody and MAAA-1181a

  • Steroid Containing MouthwashDrug

    A mouthwash containing a steroid ingredient administered in sub-study

  • Non-Steroid Containing MouthwashOther

    A mouthwash containing a non-steroid ingredient administered in sub-study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose-limiting toxicitiesTime frame: Within 8 cycles (each cycle is 21 days)
  2. Number of participants with adverse events (AEs)Time frame: When all participants have either discontinued the study or the last participant enrolled in the study has completed at least 6 months of follow up (approximately 4 years)
  3. Number of participants with Grade >/= 2 oral mucositis/stomatitis in Sub-StudyTime frame: At 8 weeks

Locations

18 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California, Los Angeles

    Los Angeles, California

  • Johns Hopkins Sibley Memorial Hospital

    Washington D.C., District of Columbia

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • Johns Hopkins University

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Tisch Cancer Institute, Icahn School of Medicine

    New York, New York

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

  • Next Oncology

    San Antonio, Texas

  • START Oncology

    San Antonio, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • National Cancer Center Hospital

    Chūōku, Japan

  • National Cancer Center Hospital East

    Kashiwa, Japan

  • Aichi Cancer Center

    Nagoya, Aichi-ken, Japan

  • The Cancer Institute Hospital of Japanese Foundation For Cancer Research

    Koto-Ku, Tokyo, Japan

  • Showa Medical University Hospital

    Shinagawa-Ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.